Russia develops potential anti-aging vaccine to slow cellular decay

Tatyana Golikova announced that Russia aims to introduce an anti-aging drug between 2028 and 2030.

MOSCOW: Russia has announced a major scientific development with the introduction of a potential “anti-aging vaccine,” a gene therapy designed to slow cellular deterioration by targeting the RAGE receptor considered a key driver of age-related changes in the human body.

Researchers have reportedly carried out experimental procedures aimed at blocking this receptor, with the goal of halting biological processes linked to aging and extending cellular longevity.

The project is being developed by the Institute of Aging Biology and Medicine as part of the country’s broader push to strengthen domestic biotechnology capabilities.

Officials say the initiative is also intended to address the economic and social challenges posed by Russia’s aging and declining population.

As a result, longevity research is being framed as both a public health priority and a matter of national importance.

Speaking at a healthy longevity conference in Saransk, researcher Sekirinsky explained that activation of the RAGE gene triggers cellular aging, while blocking it could help preserve youth at the cellular level.

Meanwhile, Deputy Prime Minister Tatyana Golikova announced that Russia aims to introduce an anti-aging drug between 2028 and 2030 under the “New Technologies for Health Preservation” national project, launched in 2025 with a budget exceeding $26 billion.

According to sources, the initiative has been strongly supported by Mikhail Kovalchuk, a key figure in Russia’s scientific community.

The announcement highlights intensifying global competition in advanced fields such as gene editing and regenerative medicine.

If successful, the development could position Russia as a leading player in the emerging anti-aging therapeutics sector.